Pasar al contenido principal

ASSESSMENT OF THE PROTECTIVE ROLE OF AHR IN HEART FAILURE. MECHANISMS OF INHIBITION OF FERROPTOSIS BY AHR ACTIVATION IN THE FAILING HEART

PID2023-148933OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2023
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Atrial Myopathy and Heart Failure: Immunomolecular Mechanisms and Clinical Implications

  • Gil Fernández, Marta
  • Bueno Sen, Andrea
  • Cantolla Pablo, Paula
  • Val Blasco, Almudena
  • Ruiz Hurtado, Gema
  • Delgado, Carmen
  • Cubillos, Carolina
  • Boscá, Lisardo
  • Fernández Velasco, María
Heart failure (HF) remains a major global health challenge defined by the inability of the heart to adequately meet systemic metabolic requirements. While ventricular dysfunction has traditionally been the primary focus in both conceptual and clinical frameworks of HF, emerging evidence highlights atrial myopathy—covering structural, functional, electrical, metabolic, and neurohormonal remodeling—as a central yet often overlooked contributor to disease progression across the HF spectrum. This review offers a comprehensive overview of the molecular and cellular mechanisms underlying atrial remodeling, with a focus on inflammation and innate immune activation as key pathogenic mediators. Among pattern recognition receptors, Toll-like receptors (TLRs) and NOD-like receptors (NLRs) play crucial roles in translating myocardial stress into pro-inflammatory, profibrotic, and pro-arrhythmic signals that exacerbate HF. By combining experimental and clinical evidence, we emphasize atrial myopathy as both a biomarker and an active driver of HF deterioration, advocating for the inclusion of atrial-targeted diagnostics and immunomodulatory therapies in future HF treatment approaches. Such a paradigm shift holds significant potential for improved risk stratification, arrhythmia prevention, attenuation of structural remodeling, and ultimately, better prognosis and clinical outcomes in this increasingly common syndrome., This work was funded by the Spanish Ministry of Science and Innovation (MICIN/AEI/10.13039/501100011033) through grants PID2023-148933OB-I00 and CNS2023-145161, and the REDINFLAMA network (grant RED2022-134511-T); by the Instituto de Salud Carlos III (ISCIII) through grants PI20/01482, PI23/01014, F21/00259, CM23/00121, CD22/00055, PMP22/00098, PT23/00028, and by CIBERCV (Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares). Funding was also provided by the European Regional Development Fund (ERDF), the European Social Fund (ESF), and the COMETA-Red (Consejo Superior de Investigaciones Científicas, CSIC). Additional support was provided by the Spanish Society of Cardiology—Translational Project 2019, and the Heart Rhythm Association (SEC, Spain) through the Asociación Insuficiencia Cardiaca (Trasplante Cardiaco) Project 20203. A.V.B. was supported by a Sara Borrell postdoctoral fellowship (CD22/00055), funded by the Instituto de Salud Carlos III (ISCIII), the European Union—NextGenerationEU, and the Spanish Recovery, Transformation and Resilience Plan (PRTR)., Peer reviewed